Collaborations and Alliances Increasing as the Market for Prefilled Syringes Matures

(Amherst, NH) – The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing market conditions, increased competition from generics, consolidation within supply chains, and healthcare administration initiatives.

The injectable drug ecosystem consists of several segments that include syringe component suppliers, syringe manufacturers, and contract filling companies. Within these layers are specialty service providers that include, among others, formulation technology developers, device designers, and physical properties testing. For small-to–mid size companies, many of these functions are outsourced. Because of the complexity of this ecosystem relative to vial packaging, the decision to develop an injectable for administration with a prefilled device is being made earlier in the drug development cycle, as product managers and marketers understand the need to take full advantage of combination product opportunities.

There are less than a dozen important prefilled syringe manufacturers worldwide. These companies have significant operations and investment in materials technology and injection device fabrication and commercialization. While several major suppliers have manufacturing sites on more than one continent, even those that are based in one regional or geographic area have extensive facilities designed to handle most or all or most of the design/development/manufacturing cycle requirements associated with syringe creation, production and commercialization.

While prefillable syringe manufacturers continue to improve and refine their products, from a materials technology standpoint the most dynamic developments are occurring in the evolution of PFS constructed of plastic rather than glass. To date, plastic PFS have made significant inroads in EMS injectables, a segment dominated by plastic PFS. Now, as materials technology continues to advance, market sector participants are targeting mainstream therapeutic drugs.

As the market matures, prefillable syringe and injector suppliers are attempting to keep pace with the changing injectables landscape, adding capacity, integrating operations in-house for capabilities that are trending up, and shedding business units and in some cases branded devices to stay current with what is perceived to be the latest injectable drug market direction .

Major therapeutic markets for self-administered subcutaneous injectables include autoimmune diseases, hormone replacement, metabolic diseases such as diabetes and osteoporosis, and blood thinners. And while oncology drugs continue to be developed for infusion in a healthcare setting, the approval of Roche’s Herceptin, an antibody indicated for treating HER2-positive breast cancer, as a subcutaneous formulation (Herceptin SC) in Europe last year is a glimpse into the future. Herceptin SC is enabled by recombinant technology supplied by Halozyme.

Detailed analysis of the global prefilled syringe market is contained in a new and comprehensive report. Prefilled Syringes in 2017 and Beyond: the Products, the Markets the Collaborations examines the prefilled syringe market as it continues to mature.

More information is available at http://www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.